Clinical trial

Diindolylmethane in Treating Patients Undergoing Surgery for Stage I or Stage II Prostate Cancer

NCT00450229

Study summary

ClinicalTrials.gov

Diindolylmethane in Treating Patients Undergoing Surgery for Stage I or Stage II Prostate Cancer

Design: INTERVENTIONAL · Status: COMPLETED · Phase: PHASE1

Loading study purpose, treatment groups and outcomes…

View the complete registry record, eligibility and contacts at ClinicalTrials.gov

Drugs and interventions used in this trial

5 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

DRUG · Unmapped registry intervention diindolylmethane Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention placebo Find medicine records · Find other trials using this name

PROCEDURE · Unmapped registry intervention therapeutic conventional surgery Find medicine records · Find other trials using this name

OTHER · Unmapped registry intervention laboratory biomarker analysis Find medicine records · Find other trials using this name

OTHER · Unmapped registry intervention pharmacological study Find medicine records · Find other trials using this name

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2007-02-01

PhasePHASE1

Conditions

Adenocarcinoma of the Prostateverified · MONDO: prostate adenocarcinoma

Prostate Cancerverified · MONDO: prostate cancer

Stage I Prostate Cancerunresolved

Stage II Prostate Cancerunresolved

Interventions

diindolylmethaneDRUG

placeboDRUG

therapeutic conventional surgeryPROCEDURE

laboratory biomarker analysisOTHER

pharmacological studyOTHER

Sponsors & collaborators

National Cancer Institute (NCI)lead sponsor

Mapped research locations

MadisonWisconsin, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT00450229 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.